Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.
US Weekly on MSN6d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, MoreCelebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...
In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback